Raghavendra Institute of Pharmaceutical Education and Research RIPER

Anantapur, India

Raghavendra Institute of Pharmaceutical Education and Research RIPER

Anantapur, India

Time filter

Source Type

Tanwar O.,Jamia Hamdard University | Deora G.S.,University of Hyderabad | Deora G.S.,University of Queensland | Janardhan S.,Raghavendra Institute of Pharmaceutical Education and Research RIPER | And 3 more authors.
Journal of Molecular Modeling | Year: 2014

The present study demonstrates and validates the discovery of two novel hydrazine derivatives as selective dipeptidyl peptidase-IV (DPP-IV) inhibitors. Virtual screening (VS) of publicly available databases was performed using virtual screening workflow (VSW) of Schrödinger software against DPP-IV and the most promising hits were selected. Selectivity was further assessed by docking the hits against homology modeled structures of DPP8 and DPP9. Two novel hydrazine derivatives were selected for further studies based on their selectivity threshold. To assess their correct binding modes and stability of their complexes with enzyme, molecular dynamic (MD) simulation studies were performed against the DPP-IV protein and the results revealed that they had a better binding affinity towards DPP-IVas compared to DPP 8 and DPP 9. The binding poses were further validated by docking these ligands with different softwares (Glide and Gold). The proposed binding modes of hydrazines were found to be similar to sitagliptine and alogliptine. Thus, the study reveals the potential of hydrazine derivatives as highly selective DPP-IV inhibitors. © Springer-Verlag 2014.


Peraman R.,Gulf Medical University | Peraman R.,Raghavendra Institute of Pharmaceutical Education and Research RIPER | Bhadraya K.,Swaroop Technology Consultancy | Padmanabha Reddy Y.,Raghavendra Institute of Pharmaceutical Education and Research RIPER
International Journal of Analytical Chemistry | Year: 2015

Very recently, Food and Drug Administration (FDA) has approved a few new drug applications (NDA) with regulatory flexibility for quality by design (QbD) based analytical approach. The concept of QbD applied to analytical method development is known now as AQbD (analytical quality by design). It allows the analytical method for movement within method operable design region (MODR). Unlike current methods, analytical method developed using analytical quality by design (AQbD) approach reduces the number of out-of-trend (OOT) results and out-of-specification (OOS) results due to the robustness of the method within the region. It is a current trend among pharmaceutical industry to implement analytical quality by design (AQbD) in method development process as a part of risk management, pharmaceutical development, and pharmaceutical quality system (ICH Q10). Owing to the lack explanatory reviews, this paper has been communicated to discuss different views of analytical scientists about implementation of AQbD in pharmaceutical quality system and also to correlate with product quality by design and pharmaceutical analytical technology (PAT). © 2015 Ramalingam Peraman et al.


Peraman R.,Gulf Medical University | Varma R.V.,Andhra University | Reddy Y.P.,Raghavendra Institute of Pharmaceutical Education and Research RIPER
Bioorganic and Medicinal Chemistry Letters | Year: 2015

Occurrence of antibacterial and antimycobacterial resistance stimulated a thrust to discover new drugs for infectious diseases. Herein we report the work on re-engineering nalidixic acid's chemical scaffold for newer leads. Stepwise clubbing of quinoxaline, 1,2,4-triazole/1,3,4-oxadiazole with nalidixic acid yielded better compounds. Compounds were screened against ciprofloxacin resistant bacteria and Mycobacterium tuberculosis H37Rv species. Results were obtained as minimum inhibitory concentration, it was evident that molecule with quinoxaline linked azide as side chain served as antitubercular lead (<6.25. μg/ml) whilst molecule with oxadiazole or triazole linked quinoxaline side chain served as anti-bacterial lead. Few compounds were significantly active against Escherichia coli and Proteus vulgaris with MIC less than 0.06. μg/ml and relatively potent than ciprofloxacin. No true compound was potentially active against Salmonella species as compared to amoxicillin. © 2015 Elsevier Ltd.


PubMed | Gulf Medical University, Raghavendra Institute of Pharmaceutical Education and Research RIPER and Andhra University
Type: Journal Article | Journal: Bioorganic & medicinal chemistry letters | Year: 2015

Occurrence of antibacterial and antimycobacterial resistance stimulated a thrust to discover new drugs for infectious diseases. Herein we report the work on re-engineering nalidixic acids chemical scaffold for newer leads. Stepwise clubbing of quinoxaline, 1,2,4-triazole/1,3,4-oxadiazole with nalidixic acid yielded better compounds. Compounds were screened against ciprofloxacin resistant bacteria and Mycobacterium tuberculosis H37Rv species. Results were obtained as minimum inhibitory concentration, it was evident that molecule with quinoxaline linked azide as side chain served as antitubercular lead (<6.25 g/ml) whilst molecule with oxadiazole or triazole linked quinoxaline side chain served as anti-bacterial lead. Few compounds were significantly active against Escherichia coli and Proteus vulgaris with MIC less than 0.06 g/ml and relatively potent than ciprofloxacin. No true compound was potentially active against Salmonella species as compared to amoxicillin.


PubMed | Swaroop Technology Consultancy, Gulf Medical University and Raghavendra Institute of Pharmaceutical Education and Research RIPER
Type: | Journal: International journal of analytical chemistry | Year: 2015

Very recently, Food and Drug Administration (FDA) has approved a few new drug applications (NDA) with regulatory flexibility for quality by design (QbD) based analytical approach. The concept of QbD applied to analytical method development is known now as AQbD (analytical quality by design). It allows the analytical method for movement within method operable design region (MODR). Unlike current methods, analytical method developed using analytical quality by design (AQbD) approach reduces the number of out-of-trend (OOT) results and out-of-specification (OOS) results due to the robustness of the method within the region. It is a current trend among pharmaceutical industry to implement analytical quality by design (AQbD) in method development process as a part of risk management, pharmaceutical development, and pharmaceutical quality system (ICH Q10). Owing to the lack explanatory reviews, this paper has been communicated to discuss different views of analytical scientists about implementation of AQbD in pharmaceutical quality system and also to correlate with product quality by design and pharmaceutical analytical technology (PAT).


Dugga H.H.T.,Raghavendra Institute of Pharmaceutical Education and Research RIPER | Peraman R.,Raghavendra Institute of Pharmaceutical Education and Research RIPER | Nayakanti D.,Andhra University
Journal of Chromatographic Science | Year: 2014

A specific, stability-indicating reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for the estimation of perindopril erbumine (PDE) in tablet dosage form. The HPLC method showed adequate separation of PDE from its degradation products. The separation was achieved on a Phenomenex Luna C18 column (250 × 4.6 mm × 5 μm) using a mobile phase composition of 0.2% trifluoroacetic acid buffer and acetonitrile in the ratio of 60:40 (pH adjusted to 3 with ammonia) at a flow rate of 1 mL/min. The injection volume was 20 μL and the wavelength of detection was kept at 215 nm. Stress studies were performed with 1 mg/mL of each drug, starting with mild conditions and followed by stronger conditions to achieve sufficient degradation at approximately 5-20%. The linearity of the proposed method was investigated in the range of 2.5 to 50 μg/mL for PDE. The limits of detection and quantification were found to be 0.75 and 2.3 μg/mL, respectively. © 2013 The Author. Published by Oxford University Press. All rights reserved.


Peraman R.,Raghavendra Institute of Pharmaceutical Education and Research RIPER | Manikala M.,Raghavendra Institute of Pharmaceutical Education and Research RIPER | Kondreddy V.K.,Raghavendra Institute of Pharmaceutical Education and Research RIPER | Yiragamreddy P.R.,Raghavendra Institute of Pharmaceutical Education and Research RIPER
Journal of Chromatographic Science | Year: 2015

A specific stability-indicating reversed-phase high-performance liquid chromatographic method was developed and validated for the estimation of meclizine hydrochloride (MEC) in tablet dosage form. The HPLC method has shown adequate separation of MEC from their degradation products. The separation was achieved on a C8 (250 mm×4.6 mm×5 μm) column using a mobile phase composition of 0.2% triethylamine in water and methanol in the ratio of 65:35(pH adjusted to 3.0 with orthophosphoric acid) with a flow rate of 1 mL/min. The wavelength of a photo-diode array detector was kept at 229 nm. Stress studies were performed initially under milder conditions followed by stronger conditions so as to get sufficient degradation around 5-20%. There were six degradation products observed with adequate separation from the analyte peak. Among those detected degradation products, structures of four degradation products were verified by comparison with known impurities of meclizine analogs. The method was validated as per the International Conference on Harmonization (Q2) guidelines. The method was specific, selective, accurate and precise to quantify meclizine in the presence of degradation products. © The Author 2015. Published by Oxford University Press.


Kumar A.K.,Raghavendra Institute of Pharmaceutical Education and Research RIPER | Mohanakrishna A.,Raghavendra Institute of Pharmaceutical Education and Research RIPER | Sudheer M.,Raghavendra Institute of Pharmaceutical Education and Research RIPER | Sai Rajesh K.,Raghavendra Institute of Pharmaceutical Education and Research RIPER | Ramalingam P.,Raghavendra Institute of Pharmaceutical Education and Research RIPER
International Journal of ChemTech Research | Year: 2011

A simple and Sensitive UV spectrophotometric method has been developed for the determination of Alprazolam in bulk and tablet dosage form. Solution of Alprazolam in 0.1N HCl shows maximum absorbance at 260 nm. Beer's law was obeyed in the concentration range of 1-70μg mL-1 with 0.022x104 mol-1 cm-1. The proposed method has been applied successfully for the analysis of drug in its tablets dosage forms. Result of percentage recovery and placebo interference shows that the method was not affected by the presence of common excepients. The percentages assay of Alprazolam in tablet was 99.4%. The method was validated by determining its sensitivity, accuracy and precession which proved suitability of the developed method for the routine estimation of Alprazolam solid dosage form.


Swaroopa Rani K.,Raghavendra Institute of Pharmaceutical Education and Research RIPER | Swapna A.,Raghavendra Institute of Pharmaceutical Education and Research RIPER | Padma A.,Raghavendra Institute of Pharmaceutical Education and Research RIPER | Chaithanya K.,Raghavendra Institute of Pharmaceutical Education and Research RIPER | And 2 more authors.
Research Journal of Pharmaceutical, Biological and Chemical Sciences | Year: 2011

A simple spectrophotometric method has been developed for the estimation of amlodipine besylate using double distilled water as a solvent. Amlodipine besylate is an anti-hypertensive and an antianginal agent. Amlodipine besylate has shown maximum absorption at 364nm. The calibration was found to be linear in the concentration range of 6-80μg/ml, with regression value of 0.998. Recovery studies were carried out and the average percentage recovery of the sample was found to be 100.4%. Thus the method was found to be accurate. Precesion study was carried and expressed in terms of %RSD, which was found to be less than 2%. So the method was precise. The drug was subjected to oxidation, hydrolysis, heat and photolysis to apply stress conditions. Degradation products resulting from stress studies did not interfere with the detection of amlodipine besylate. © 2010 RJPBCS.


PubMed | Raghavendra Institute of Pharmaceutical Education and Research RIPER
Type: Evaluation Studies | Journal: Journal of chromatographic science | Year: 2015

A specific stability-indicating reversed-phase high-performance liquid chromatographic method was developed and validated for the estimation of meclizine hydrochloride (MEC) in tablet dosage form. The HPLC method has shown adequate separation of MEC from their degradation products. The separation was achieved on a C8 (250 mm4.6 mm5 m) column using a mobile phase composition of 0.2% triethylamine in water and methanol in the ratio of 65:35(pH adjusted to 3.0 with orthophosphoric acid) with a flow rate of 1 mL/min. The wavelength of a photo-diode array detector was kept at 229 nm. Stress studies were performed initially under milder conditions followed by stronger conditions so as to get sufficient degradation around 5-20%. There were six degradation products observed with adequate separation from the analyte peak. Among those detected degradation products, structures of four degradation products were verified by comparison with known impurities of meclizine analogs. The method was validated as per the International Conference on Harmonization (Q2) guidelines. The method was specific, selective, accurate and precise to quantify meclizine in the presence of degradation products.

Loading Raghavendra Institute of Pharmaceutical Education and Research RIPER collaborators
Loading Raghavendra Institute of Pharmaceutical Education and Research RIPER collaborators